Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Miner, Jeffrey N.
Tan, Philip K.
Hagerty, David T.
Funding for this research was provided by:
Ardea Biosciences, Inc., San Diego, CA, a wholly owned subsidiary of AstraZeneca PLC